Search
Metiamide
go.drugbank.com/drugs/DB08805ExperimentalMetiamide is an H-2 receptor antagonist derived from burimamide. It was an intermediate product on the path to developing cimetidine.
Indecainide
go.drugbank.com/drugs/DB00192ApprovedIndecainide has local anesthetic activity and belongs to the membrane stabilizing (Class 1) group of antiarrhythmic agents; it has electrophysiologic effects characteristic of the IC class of antiarrhythmics
Ritiometan
go.drugbank.com/drugs/DB13267ApprovedRitiometan is a nasal spray which is marketed by the name Nécyrane in France. It is indicated for use in viral rhinitis/ the common cold.
Phloxine B
go.drugbank.com/drugs/DB13911ApprovedWithdrawnPhloxine B (commonly known simply as phloxine, also known as D&C RED NO. 28) is a color additive which is used both as an inactive ingredient to provide color to products, or as a colorant in dental disclosing
Categories: Compounds used in a research, industrial, or household settingPerospirone
go.drugbank.com/drugs/DB08922InvestigationalIt is commonly present as the hydrated hydrochloride salt form. … It also displays affinity towards 5HT1A receptors as a partial agonist.
Synonyms: cis-N-(4-(4-(1,2-Benzisothiazol-3-yl)-1-piperazinyl)butyl)-1,2-cyclohexanedicarboximideTrofinetide
go.drugbank.com/drugs/DB06045Approved[A258453] Trofinetide is marketed as DAYBUE and DAYBUE STIX in the United States, as DAYBUE in Canada, and as DAYBU in the European Union. … Trofinetide is a novel synthetic analog of [glypromate], also known as glycine–proline–glutamate (GPE), a naturally occurring protein in the brain and the N-terminal tripeptide of insulin-like growth factor
Neisseria meningitidis group A capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB15680ApprovedInvestigationalNeisseria meningitidis group C capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB15681ApprovedInvestigationalProducts: NeisVac-C Injektionssuspension in einer FertigspritzeAlvespimycin
go.drugbank.com/drugs/DB12442InvestigationalIt has been used in trials studying the treatment of solid tumor in various cancer as an antitumor agent. … In comparison to the first HSP90 inhibitor tanespimycin, it exhibits some pharmacologically desirable properties such as reduced metabolic liability, lower plasma protein binding, increased water solubility
Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen
go.drugbank.com/drugs/DB15683ApprovedInvestigational